Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
about
A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to TumorigenesisClinical relevance of circulating cell-free microRNAs in ovarian cancerNew Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid BiopsiesGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapymiR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal TransitionA MALAT1/HIF-2α feedback loop contributes to arsenite carcinogenesisThe circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.microRNA-200a-3p enhances mitochondrial elongation by targeting mitochondrial fission factor.The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition.Identification of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma.Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through.Research Progress of MicroRNA in Early Detection of Ovarian CancerDiagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b.miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.MicroRNAs in extracellular vesicles: potential cancer biomarkers.RNA in extracellular vesicles.MicroRNAs in gynecological cancers: Small molecules with big implications.Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.The miR-200 family in ovarian cancer.microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice.A combination of circulating miRNAs for the early detection of ovarian cancer.Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer.Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer.The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma.Exosomal microRNAs as tumor markers in epithelial ovarian cancerLiquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
P2860
Q26746952-D87B10D6-B815-42A3-9CF6-4697A4A38D7AQ26747154-3F19E60C-60A2-42CF-812F-7241568F41ABQ26748881-DC9438B5-7CE0-49FB-8D00-FB8C91ED5D99Q26769604-76CAF531-A0AE-4E46-917D-F9E207F880D9Q28071987-273E62C3-CAFC-4641-B797-8D70AB81661DQ28394359-87EF32CF-2044-401B-91A1-4E54509D8BA9Q33597590-37B23BC6-E01B-42CC-BBE9-031ACEEA0D3CQ33707623-322D9EF2-CF85-4E95-BB83-258951F2577EQ33838714-4C3BD50E-1948-415E-AD00-8A6CC080A8FCQ36483432-F0AFB0E3-2A9E-4F97-BDF6-D5D713EBEE3EQ36503366-FA8FB16D-979C-4580-A7CF-095C305CD32AQ36701651-2CBEC259-B57E-43EA-A3B5-BC501B3596EFQ37086163-97FDFD97-803F-4114-AB88-84D9220709AFQ37672829-74D65B00-9F4A-4D06-A5C5-699B5823F08AQ37697194-95CB4817-6396-47DB-AC35-60FC4A87C30FQ38766067-0757E235-1FF9-48C5-9B16-7DFEA9229F4DQ38812266-54C1540D-27F7-4C1B-8C7E-EB6D615F2692Q38887851-9B6DF7B8-CFFE-4E9E-8DB7-BDB3FE1BD7E9Q39107313-12D167A7-8528-44EF-A6DD-D3A3CED2472EQ39333266-63347986-C0A8-4D10-9175-1754B2D38E6BQ39391417-0CADCA1D-600A-485B-A32C-D7B7E40B120EQ42371676-459DC5A7-7F83-4098-A5A2-FE7A391E2326Q43279631-1F3E3884-9659-46CA-97D8-AF9C508D20D1Q44833373-240112BD-A104-40C4-BD42-B387391E81A7Q45777871-FB97EBDD-40D6-489B-AA8D-032DC0BD5696Q45944325-4F173DE3-3F7D-4EF4-974C-42C1AC299B34Q47097248-E6C6A811-4FBB-4064-911F-469B2F3D9A3BQ47652779-7050E251-91E0-4C4B-8F05-0E9449F18B19Q48000348-0CBFEBE7-83D0-43D9-BB06-181A7BC8C677Q52590673-52566A55-315F-4F71-88C6-5D3399E4864AQ58776553-BA27ED6B-55DD-465A-A751-B96250F32097Q58799160-5D96F2FA-B850-4D52-86D3-F3DCD38F0DA9
P2860
Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Expression of serum miR-200a, ...... clinicopathological features.
@en
type
label
Expression of serum miR-200a, ...... clinicopathological features.
@en
prefLabel
Expression of serum miR-200a, ...... clinicopathological features.
@en
P2093
P2860
P1476
Expression of serum miR-200a, ...... clinicopathological features.
@en
P2093
P2860
P2888
P304
P356
10.1007/S12094-015-1303-1
P577
2015-06-11T00:00:00Z